A Profile of Nanoparticle-Based Plasma Neurodegenerative Biomarkers for Cognitive Function Among Patients Undergoing Hemodialysis

References

• Kurella Tamura M, Yaffe K. Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies. Kidney Int. 2011;79:14–22. doi:10.1038/ki.2010.336
   PubMed Web of Science ®Google Scholar
• Chen JB, Chang CC, Li LC, et al. Mutual interaction of clinical factors and specific microRNAs to predict mild cognitive impairment in patients receiving hemodialysis. Cells. 2020;9:2303. doi:10.3390/cells9102303
   PubMed Web of Science ®Google Scholar
• Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis. 2008;15:123–132. doi:10.1053/j.ackd.2008.01.010
   PubMed Web of Science ®Google Scholar
• Wada M, Nagasawa H, Iseki C, et al. Cerebral small vessel disease and chronic kidney disease (CKD): results of a cross-sectional study in community-based Japanese elderly. J Neurol Sci. 2008;272:36–42. doi:10.1016/j.jns.2008.04.029
   PubMed Web of Science ®Google Scholar
• McAdams-DeMarco MA, Tan J, Salter ML, et al. Frailty and cognitive function in incident hemodialysis patients. Clin J Am Soc Nephrol. 2015;10:2181–2189. doi:10.2215/CJN.01960215
   PubMed Web of Science ®Google Scholar
• Moorhouse P, Rockwood K. Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol. 2008;7:246–255. doi:10.1016/S1474-4422(08)70040-1
   PubMed Web of Science ®Google Scholar
• Watanabe K, Watanabe T, Nakayama M. Cerebro-renal interactions: impact of uremic toxins on cognitive function. Neurotoxicology. 2014;44c:184–193. doi:10.1016/j.neuro.2014.06.014
   Web of Science ®Google Scholar
• Chou FF, Chen JB, Hsieh KC, Liou CW. Cognitive changes after parathyroidectomy in patients with secondary hyperparathyroidism. Surgery. 2008;143:526–532. doi:10.1016/j.surg.2007.11.019
   PubMed Web of Science ®Google Scholar
• Madero M, Gul A, Sarnak MJ. Cognitive function in chronic kidney disease. Semin Dial. 2008;21:29–37. doi:10.1111/j.1525-139X.2007.00384.x
   PubMed Web of Science ®Google Scholar
• Kallenberg MH, Kleinveld HA, Dekker FW, et al. Functional and cognitive impairment, frailty, and adverse health outcomes in older patients reaching ESRD-A systematic review. Clin J Am Soc Nephrol. 2016;11:1624–1639. doi:10.2215/CJN.13611215
   PubMed Web of Science ®Google Scholar
• Liang X, Wen J, Ni L, et al. Altered pattern of spontaneous brain activity in the patients with end-stage renal disease: a resting-state functional MRI study with regional homogeneity analysis. PLoS One. 2013;8:e71507. doi:10.1371/journal.pone.0071507
   PubMed Web of Science ®Google Scholar
• Zheng G, Wen J, Zhang L, et al. Altered brain functional connectivity in hemodialysis patients with end-stage renal disease: a resting-state functional MR imaging study. Metab Brain Dis. 2014;29:777–786. doi:10.1007/s11011-014-9568-6
   PubMed Web of Science ®Google Scholar
• O’Doherty J, Dayan P, Schultz J, Deichmann R, Friston K, Dolan RJ. Dissociable roles of ventral and dorsal striatum in instrumental conditioning. Science. 2004;304:452–454. doi:10.1126/science.1094285
   PubMed Web of Science ®Google Scholar
• Hansson O, Zetterberg H, Buchhave P, et al. Prediction of Alzheimer’s disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord. 2007;23:316–320. doi:10.1159/000100926
   PubMed Web of Science ®Google Scholar
• Lui JK, Laws SM, Li QX, et al. Plasma amyloid-beta as a biomarker in Alzheimer’s disease: the AIBL study of aging. J Alzheimers Dis. 2010;20:1233–1242. doi:10.3233/JAD-2010-090249
   PubMed Web of Science ®Google Scholar
• Shi Y, Liu Z, Shen Y, Zhu H. A novel perspective linkage between kidney function and Alzheimer’s disease. Front Cell Neurosci. 2018;12:384. doi:10.3389/fncel.2018.00384
   PubMed Web of Science ®Google Scholar
• Brici D, Götz J, Nisbet RM. A novel antibody targeting tau phosphorylated at serine 235 detects neurofibrillary tangles. J Alzheimers Dis. 2018;61:899–905. doi:10.3233/JAD-170610
   PubMed Web of Science ®Google Scholar
• Harrington CR, Wischik CM, McArthur FK, Taylor GA, Edwardson JA, Candy JM. Alzheimer’s-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. Lancet. 1994;343:993–997. doi:10.1016/S0140-6736(94)90124-4
   PubMed Web of Science ®Google Scholar
• Chiu MJ, Yang SY, Horng HE, et al. Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer’s disease. ACS Chem Neurosci. 2013;4:1530–1536. doi:10.1021/cn400129p
   PubMed Web of Science ®Google Scholar
• Mattsson N, Zetterberg H, Janelidze S, et al. Plasma tau in Alzheimer disease. Neurology. 2016;87:1827–1835. doi:10.1212/WNL.0000000000003246
   PubMed Web of Science ®Google Scholar
• Chiu MJ, Chen TF, Hu CJ, et al. Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer’s disease - A cross-validation study. Nanomedicine. 2020;28:102182. doi:10.1016/j.nano.2020.102182
   PubMed Web of Science ®Google Scholar
• Song C, Deng P, Que L. Rapid multiplexed detection of beta-amyloid and total-tau as biomarkers for Alzheimer’s disease in cerebrospinal fluid. Nanomedicine. 2018;14:1845–1852. doi:10.1016/j.nano.2018.05.013
   PubMed Web of Science ®Google Scholar
• Yang SY, Liu HC, Chen WP. Immunomagnetic reduction detects plasma Aβ(1-42) levels as a potential dominant indicator predicting cognitive decline. Neurol Ther. 2020;9:435–442. doi:10.1007/s40120-020-00215-2
   PubMed Web of Science ®Google Scholar
• Daugirdas JT. The post: pre-dialysis plasma urea nitrogen ratio to estimate K.t/V and NPCR: mathematical modeling. Int J Artif Organs. 1989;12:411–419.
   PubMed Web of Science ®Google Scholar
• Yang SY, Chiu MJ, Chen TF, Horng HE. Detection of plasma biomarkers using immunomagnetic reduction: a promising method for the early diagnosis of Alzheimer’s disease. Neurol Ther. 2017;6:37–56. doi:10.1007/s40120-017-0075-7
   PubMed Web of Science ®Google Scholar
• Yu RL, Lee WJ, Li JY, et al. Evaluating mild cognitive dysfunction in patients with parkinson’s disease in clinical practice in Taiwan. Sci Rep. 2020;10:1014. doi:10.1038/s41598-020-58042-2
   PubMed Web of Science ®Google Scholar
• Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–572. doi:10.1192/bjp.140.6.566
   PubMed Web of Science ®Google Scholar
• Drew DA, Weiner DE, Sarnak MJ. Cognitive impairment in CKD: pathophysiology, management, and prevention. Am J Kidney Dis. 2019;74:782–790. doi:10.1053/j.ajkd.2019.05.017
   PubMed Web of Science ®Google Scholar
• Chien CW, Lin YC, Huang SK, Chen PE, Tung TH. A population-based study of the association between hemodialysis and cognitive impairment. Asia Pac Psychiatry. 2020;12:e12404. doi:10.1111/appy.12404
   PubMed Web of Science ®Google Scholar
• Tholen S, Schmaderer C, Chmielewski S, et al. Reduction of Amyloid-β plasma levels by hemodialysis: an anti-amyloid treatment strategy? J Alzheimers Dis. 2016;50:791–796. doi:10.3233/JAD-150662
   PubMed Web of Science ®Google Scholar
• Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR. Serum creatinine levels correlate with plasma amyloid Beta protein. Alzheimer Dis Assoc Disord. 2002;16:187–190. doi:10.1097/00002093-200207000-00009
   PubMed Web of Science ®Google Scholar
• Kitaguchi N, Tatebe H, Sakai K, et al. Influx of tau and amyloid-β proteins into the blood during hemodialysis as a therapeutic extracorporeal blood amyloid-β removal system for Alzheimer’s disease. J Alzheimers Dis. 2019;69:687–707. doi:10.3233/JAD-190087
   PubMed Web of Science ®Google Scholar
• Bobot M, Thomas L, Moyon A, et al. Uremic toxic blood-brain barrier disruption mediated by AhR activation leads to cognitive impairment during experimental renal dysfunction. J Am Soc Nephrol. 2020;31:1509–1521. doi:10.1681/ASN.2019070728
   PubMed Web of Science ®Google Scholar
• Rembach A, Watt AD, Wilson WJ, et al. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer’s disease as measured by cognitive decline and change in neocortical amyloid burden. J Alzheimers Dis. 2014;40:95–104. doi:10.3233/JAD-131802
   PubMed Web of Science ®Google Scholar
• Kitaguchi N, Hasegawa M, Ito S, et al. A prospective study on blood Aβ levels and the cognitive function of patients with hemodialysis: a potential therapeutic strategy for Alzheimer’s disease. J Neural Transm. 2015;122:1593–1607. doi:10.1007/s00702-015-1431-3
   PubMed Web of Science ®Google Scholar
• Pascale CL, Miller MC, Chiu C, et al. Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent. Fluids Barriers CNS. 2011;8:21. doi:10.1186/2045-8118-8-21
   PubMedGoogle Scholar
• Hou YC, Huang CL, Lu CL, et al. The role of plasma neurofilament light protein for assessing cognitive impairment in patients with end-stage renal disease. Front Aging Neurosci. 2021;13:657794. doi:10.3389/fnagi.2021.657794
   PubMed Web of Science ®Google Scholar
• Hong CH, Falvey C, Harris TB, et al. Anemia and risk of dementia in older adults: findings from the Health ABC study. Neurology. 2013;81:528–533.
   PubMed Web of Science ®Google Scholar
• Llewellyn DJ, Langa KM, Friedland RP, Lang IA. Serum albumin concentration and cognitive impairment. Curr Alzheimer Res. 2010;7:91–96. doi:10.2174/156720510790274392
   PubMed Web of Science ®Google Scholar
• Hu CJ, Chiu MJ, Pai MC, et al. Assessment of high risk for Alzheimer’s Disease using plasma biomarkers in subjects with normal cognition in Taiwan: a preliminary study. J Alzheimers Dis Rep. 2021;5:761–770. doi:10.3233/ADR-210310
   PubMedGoogle Scholar